It is being gradually recognized that portal vein thrombosis (PVT) is negatively associated with the prognosis of cirrhosis.[12] But the standard treatment algorithm remains lacking.[3] Anticoagulation, which is a widely available treatment option for venous thromboembolism, is also employed for the management of PVT in cirrhotic patients.[4] Retrospective case series demonstrated a relatively low risk of anticoagulation-related bleeding and a high rate of portal vein recanalization after anticoagulation,[34] which provided the preliminary support for the use of anticoagulation in cirrhosis with PVT. However, the clinicians are very cautious of the potential bleeding secondary to anticoagulation, because cirrhosis itself has a bleeding tendency.In the dilemma of whether or not anticoagulation therapy should be employed, the investigators would rather pay more attention to the natural history of PVT in cirrhosis in the absence of any interventions. To our knowledge, spontaneous portal vein recanalization in cirrhosis has been evaluated by at least three previous case series.[567] The incidence of spontaneous recanalization varies from 30% to 50% in cirrhotic patients with PVT.In this issue of The Saudi Journal of Gastroenterology, the concept of spontaneous portal vein recanalization has been further reinforced.[8] The investigators found that partial PVT could be spontaneously recanalized or unchanged in 72.7% (16/22) of patients, and worsened in only 27.3% (6/22) of patients.[8] More importantly, in spite of a small sample size (n = 22), the study showed a significantly higher incidence of hepatic decompensation and mortality in the cirrhotic patients with worsened PVT than in those with recanalized or unchanged PVT.[8] In line with the previous studies,[5] these impressive findings suggested that anticoagulation therapy should be selectively performed in patients who would develop the thrombus extension, thereby improving survival; by contrast, it is unnecessary in those who would develop the spontaneous thrombus resolution. However, the accurate predictors of spontaneous recanalization remain poorly recognized in this study. Therefore, the behavior to stop any interventions for partial PVT in all cirrhotic patients might be radical.In accordance with previous studies,[5] the investigators also found that the severity of liver function (i.e. MELD score) was the only independent predictor for the survival and hepatic decompensation in the multivariate Cox regression analysis. In the absence of any detailed information, we fail to clearly understand whether or not the progression of PVT had been incorporated as a variable into the multivariate analysis. But it appeared to be rational that the worsened PVT and deteriorated liver function jointly increased the mortality. This consideration could be potentially supported by the accumulated evidence regarding a vicious cycle between the development of PVT and deterioration of liver function [Figure 1]. First, the portal vein flow velocity decreases with worsening liver fibrosis and liver function.[910] Subsequently, a decreased portal vein flow velocity predicts a higher risk of developing PVT.[11] portal vein flow velocity decreases with worsening liver fibrosis and liver function.[910] Subsequently, a decreased portal vein flow velocity predicts a higher risk improved liver function, thereby producing the scouring effect and spontaneously resolving the thrombus within the portal vein.[12]
Figure 1
A scheme regarding the association between the severity of liver function and development of portal vein thrombosis
A scheme regarding the association between the severity of liver function and development of portal vein thrombosisCollectively, spontaneous portal vein recanalization can be frequently observed in patients with partial PVT. This phenomenon may be attributed to the improvement of liver function. In addition, further work should focus on identifying the candidates who will develop the thrombus extension or is suitable for anticoagulation therapy.
Authors: B V John; R Konjeti; A Aggarwal; R Lopez; A Atreja; C Miller; N N Zein; W D Carey Journal: Ann Hepatol Date: 2013 Nov-Dec Impact factor: 2.400
Authors: Maria Assunta Zocco; Enrico Di Stasio; Raimondo De Cristofaro; Marialuisa Novi; Maria Elena Ainora; Francesca Ponziani; Laura Riccardi; Stefano Lancellotti; Angelo Santoliquido; Roberto Flore; Maurizio Pompili; Gian Lodovico Rapaccini; Paolo Tondi; Giovanni Battista Gasbarrini; Raffaele Landolfi; Antonio Gasbarrini Journal: J Hepatol Date: 2009-04-23 Impact factor: 25.083